A Phase 4 interventional study of Celecoxib and Loxoprofen in Healthy Volunteers, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 3 sites in Japan. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Celecoxib
Drug: Loxoprofen
Drug: Placebo
Celecoxib 100mg tablet twice a day with meal for 2 weeks
Loxoprofen 60mg tablet three times a day with meal for 2 weeks
Placebo tablet three times a day with meal for 2 weeks
Incidence of Gastroduodenal Ulcers
The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.
Time frame: 2 weeks
Incidence of Any Gastric, and Duodenal Ulcers
The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.
Time frame: 2 weeks
Incidence of Any Gastroduodenal, Gastric, and Duodenal Ulcers and/or Erosions
The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.
Time frame: 2 weeks
Post-treatment Gastroduodenal Endoscopic Scores (According to Mucosal Grading Scale)
Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer)
Time frame: 2 weeks
Number of Gastroduodenal Ulcers in Each Subject
Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.)
Time frame: 2 weeks
Number of Gastroduodenal Erosions in Each Subject
Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.)
Time frame: 2 weeks
Incidence of Treatment-emergent, All-causality GI Body System Adverse Events
The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.)
Time frame: 2 weeks
Subjects were screened at 3 centers in Japan.
| Milestone | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Started | 76 | 76 | 37 |
| Completed | 74 | 75 | 37 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 |
The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.
| Percent | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Incidence of Gastroduodenal Ulcers | 1.4 | 27.6 | 2.7 |
The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.
| Percent | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Gastric ulcers | 0 | 25.0 | 2.7 |
| Duodenal ulcers | 1.4 | 5.3 | 0 |
The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.
| Percent | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Gastroduodenal ulcers and/or erosions | 36.5 | 53.9 | 24.3 |
| Gastric ulcers and/or erosions | 35.1 | 53.9 | 24.3 |
| Duodenal ulcers and/or erosions | 4.1 | 5.3 | 0 |
Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer)
| Participants | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Score 0 | 38 | 33 | 22 |
| Score 1 | 8 | 2 | 6 |
| Score 2 | 1 | 0 | 0 |
| Score 3 | 22 | 19 | 8 |
| Score 4 | 4 | 1 | 0 |
| Score 5 | 0 | 0 | 0 |
| Score 6 | 0 | 0 | 0 |
| Score 7 | 1 | 21 | 1 |
Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.)
| Participants | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| 0 ulcer | 73 | 55 | 36 |
| 1 ulcer | 1 | 10 | 1 |
| 2 ulcers | 0 | 5 | 0 |
| 3 ulcers | 0 | 2 | 0 |
| 4 ulcers | 0 | 0 | 0 |
| 5 ulcers | 0 | 0 | 0 |
| 6 ulcers | 0 | 1 | 0 |
| 7 ulcers | 0 | 2 | 0 |
| 8 ulcers | 0 | 1 | 0 |
| 9 ulcers | 0 | 0 | 0 |
| 10 or more ulcers | 0 | 0 | 0 |
Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.)
| Participants | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| 0 erosion | 47 | 41 | 29 |
| 1 erosion | 14 | 13 | 5 |
| 2 erosions | 4 | 3 | 1 |
| 3 erosions | 5 | 9 | 2 |
| 4 erosions | 0 | 4 | 0 |
| 5 erosions | 0 | 3 | 0 |
| 6 erosions | 2 | 1 | 0 |
| 7 erosions | 1 | 1 | 0 |
| 8 erosions | 0 | 1 | 0 |
| 9 erosions | 0 | 0 | 0 |
| 10 or more erosions | 1 | 0 | 0 |
The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.)
| Percent | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Incidence of Treatment-emergent, All-causality GI Body System Adverse Events | 24.3 | 47.4 | 16.2 |
Collected over 2 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib | — | 0/76 (0%) | 19/76 (25%) |
| Loxoprofen | — | 0/76 (0%) | 37/76 (48.7%) |
| Placebo | — | 0/37 (0%) | 8/37 (21.6%) |
| Event | Celecoxib | Loxoprofen | Placebo |
|---|---|---|---|
| Gastritis erosiveGastrointestinal disorders | 8/76 | 28/76 | 3/37 |
| Erosive duodenitisGastrointestinal disorders | 1/76 | 5/76 | 0/37 |
| DiarrhoeaGastrointestinal disorders | 1/76 | 2/76 | 2/37 |
| Abdominal discomfortGastrointestinal disorders | 2/76 | 4/76 | 0/37 |
| Gastric ulcerGastrointestinal disorders | 0/76 | 4/76 | 0/37 |
| SomnolenceNervous system disorders | 1/76 | 4/76 | 0/37 |
| Abdominal distensionGastrointestinal disorders | 0/76 | 3/76 | 0/37 |
| DyspepsiaGastrointestinal disorders | 1/76 | 0/76 | 1/37 |
| OesophagitisGastrointestinal disorders | 0/76 | 0/76 | 1/37 |
| Bilirubin conjugated increasedInvestigations | 0/76 | 0/76 | 1/37 |
| Age, Continuous(Years) | Celecoxib | Loxoprofen | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.5 ± 9.65 | 57.8 ± 9.38 | 59.1 ± 9.18 | 57.5 ± 9.45 |
| Sex: Female, Male(Participants) | Celecoxib | Loxoprofen | Placebo | Total |
|---|---|---|---|---|
| Female | 54 | 55 | 26 | 135 |
| Male | 22 | 21 | 11 | 54 |
| Helicobacter pylori (H. pylori) status(Participants) | Celecoxib | Loxoprofen | Placebo | Total |
|---|---|---|---|---|
| Positive | 32 | 33 | 16 | 81 |
| Negative | 44 | 43 | 21 | 108 |
The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →